Drug-induced interstitial lung disease: a narrative review of a clinical conundrum

References

• Skeoch S, Weatherley N, Swift AJ, et al. Drug-induced interstitial lung disease: a systematic review. J Clin Med. 2018 Oct 15;7(10):356. doi: 10.3390/jcm7100356
   PubMed Web of Science ®Google Scholar
• Camus P, Padilla ML, Camus P. The drug-induced respiratory disease website. Immunol Allergy Clin North Am [Internet]. [cited 2023 Sep 10];43(2):341–357. Available from: http://www.pneumotox.com/drug/index
   PubMedGoogle Scholar
• Travis WD, Costabel U, Hansell DM, et al. An official American thoracic society/European respiratory society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013 Sep 15;188(6):733–748. doi: 10.1164/rccm.201308-1483ST
   PubMed Web of Science ®Google Scholar
• Camus P, Fanton A, Bonniaud P, et al. Interstitial lung disease induced by drugs and radiation. Respiration. 2004 Jul;71(4):301–326.
   PubMed Web of Science ®Google Scholar
• Johkoh T, Lee KS, Nishino M, et al. Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: a position paper from the Fleischner society. Radiology. 2021 Mar;298(3):550–566.
   PubMed Web of Science ®Google Scholar
• Program CTE Common terminology criteria for adverse events [Internet]. 2017 Nov 27 [cited 2023 Sep 11]. Version 5.0. Available from: http://ctep.cancer.gov
   Google Scholar
• Duchemann B, Annesi-Maesano I, Jacobe de Naurois C, et al. Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of greater Paris. Eur Respir J. 2017 Aug;50(2):1602419.
   PubMed Web of Science ®Google Scholar
• Hyldgaard C, Hilberg O, Muller A, et al. A cohort study of interstitial lung diseases in central Denmark. Respir med. 2014 May;108(5):793–799.
   PubMed Web of Science ®Google Scholar
• Gemma A, Kudoh S, Ando M, et al. Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer. Cancer Sci. 2014 Dec;105(12):1584–1590.
   PubMed Web of Science ®Google Scholar
• Miyagahara T, Fujimori N, Ueda K, et al. Incidence and appropriate management of drug-induced interstitial lung disease in Japanese patients with unresectable pancreatic cancer: a multicenter retrospective study. Asia Pac J Clin Oncol. 2023 Aug;19(4):533–541.
   PubMed Web of Science ®Google Scholar
• Pinheiro L, Blake K, Januskiene J, et al. Geographical variation in reporting interstitial lung disease as an adverse drug reaction: findings from an European Medicines Agency analysis of reports in EudraVigilance. Pharmacoepidemiol Drug Saf. 2016 06;25(6):705–712. doi: 10.1002/pds.3998
   PubMed Web of Science ®Google Scholar
• Camus P, Martin WJ 2nd, Rosenow EC 3rd. Amiodarone pulmonary toxicity. Clin Chest Med. 2004 Mar;25(1):65–75. doi: 10.1016/S0272-5231(03)00144-8
   PubMed Web of Science ®Google Scholar
• Andersen MD, Kamper P, d’Amore A, et al. The incidence of bleomycin induced lung toxicity is increased in Hodgkin lymphoma patients over 45 years exposed to granulocyte-colony stimulating growth factor (dagger). Leuk Lymphoma. 2019 Apr;60(4):927–933.
   PubMed Web of Science ®Google Scholar
• Conway R, Low C, Coughlan RJ, et al. Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis & Rheumat. 2014 Apr;66(4):803–812.
   PubMed Web of Science ®Google Scholar
• Udagawa C, Horinouchi H, Shiraishi K, et al. Whole genome sequencing to identify predictive markers for the risk of drug-induced interstitial lung disease. PloS One. 2019;14(10):e0223371. doi: 10.1371/journal.pone.0223371
   PubMed Web of Science ®Google Scholar
• Zhao M, Ma J, Li M, et al. Cytochrome P450 enzymes and drug metabolism in humans. Int J Mol Sci. 2021 Nov 26;22(23):12808. doi: 10.3390/ijms222312808
   PubMed Web of Science ®Google Scholar
• Wijnen PA, Drent M, Nelemans PJ, et al. Role of cytochrome P450 polymorphisms in the development of pulmonary drug toxicity: a case-control study in the Netherlands. Drug Saf. 2008;31(12):1125–1134. doi: 10.2165/0002018-200831120-00008
   PubMed Web of Science ®Google Scholar
• Schwaiblmair M, Behr W, Foerg W, et al. Cytochrome P450 polymorphisms and drug-induced interstitial lung disease. Expert Opin Drug Metab Toxicol. 2011 Dec;7(12):1547–1560.
   PubMed Web of Science ®Google Scholar
• Nishimura M, Toyoda M, Takenaka K, et al. The combination of HLA-B*15: 01 and DRB1*15: 01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol. 2016 Jun;77(6):1165–1170.
   PubMed Web of Science ®Google Scholar
• Imatoh T, Ushiki A, Ota M, et al. Association of HLA-DRB1*04: 05 allele with drug-induced interstitial lung disease in Japanese population. Pharmacogenomics J. 2020 Dec;20(6):823–830.
   PubMed Web of Science ®Google Scholar
• Bluett J, Owen SA, Massey J, et al. HLA-A 31: 01 is not associated with the development of methotrexate pneumonitis in the UK population: results from a genome-wide association study. Ann Rheum Dis. 2017 Dec;76(12):e51.
   PubMed Web of Science ®Google Scholar
• Kudoh S, Kato H, Nishiwaki Y, et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med. 2008 Jun 15;177(12):1348–1357. doi: 10.1164/rccm.200710-1501OC
   PubMed Web of Science ®Google Scholar
• Johkoh T, Sakai F, Kusumoto M, et al. Association between baseline pulmonary status and interstitial lung disease in patients with non-small-cell lung cancer treated with erlotinib–a cohort study. Clin Lung Cancer. 2014 Nov;15(6):448–454.
   PubMed Web of Science ®Google Scholar
• Gemma A, Kusumoto M, Kurihara Y, et al. Interstitial Lung disease onset and its risk factors in Japanese patients with ALK-Positive NSCLC after treatment with crizotinib. J Thorac Oncol. 2019 Apr;14(4):672–682.
   PubMed Web of Science ®Google Scholar
• Miyamoto A, Michimae H, Nakahara Y, et al. Chemotherapy versus best supportive care in advanced lung cancer and idiopathic interstitial pneumonias: a retrospective multi-centre cohort study. Respir Investig. 2023 Mar;61(2):284–295.
   PubMed Web of Science ®Google Scholar
• Chen H, Senan S, Nossent EJ, et al. Treatment-related toxicity in patients with early-stage non-small cell lung cancer and coexisting interstitial lung disease: a systematic review. Int J Radiat Oncol Biol Phys. 2017 Jul 1;98(3):622–631. doi: 10.1016/j.ijrobp.2017.03.010
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Shimizu J, Hasegawa T, et al. Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysis. BMC Cancer. 2021 Aug 16;21(1):924. doi: 10.1186/s12885-021-08661-3
   PubMed Web of Science ®Google Scholar
• Sears CR, Peikert T, Possick JD, et al. Knowledge gaps and research priorities in immune checkpoint inhibitor-related pneumonitis. An Off Am Thoracic Soc Res Statement Am J Respir Crit Care Med. 2019 Sep 15;200(6):e31–e43. doi: 10.1164/rccm.201906-1202ST
   Google Scholar
• Shimoji K, Masuda T, Yamaguchi K, et al. Association of preexisting interstitial lung abnormalities with immune checkpoint inhibitor-induced interstitial lung disease among patients with nonlung cancers. JAMA Netw Open. 2020 Nov 2;3(11):e2022906. doi: 10.1001/jamanetworkopen.2020.22906
   PubMed Web of Science ®Google Scholar
• Nakanishi Y, Masuda T, Yamaguchi K, et al. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer. Respir Investig. 2019 Sep;57(5):451–459.
   PubMed Web of Science ®Google Scholar
• Hatabu H, Hunninghake GM, Richeldi L, et al. Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. Lancet Respir Med. 2020 Jul;8(7):726–737.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Yano Y, Kuge T, et al. Safety and effectiveness of pirfenidone combined with carboplatin-based chemotherapy in patients with idiopathic pulmonary fibrosis and non-small cell lung cancer: a retrospective cohort study. Thorac Cancer. 2020 Nov;11(11):3317–3325.
   PubMed Web of Science ®Google Scholar
• Otsubo K, Kishimoto J, Ando M, et al. Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial. Eur Respir J. 2022 Dec;60(6):2200380.
   PubMed Web of Science ®Google Scholar
• Sawada T, Inokuma S, Sato T, et al. Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford). 2009 Sep;48(9):1069–1072.
   PubMed Web of Science ®Google Scholar
• Suissa S, Hudson M, Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum. 2006 May;54(5):1435–1439. doi: 10.1002/art.21806
   PubMedGoogle Scholar
• Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum. 2014 Apr;43(5):613–626. doi: 10.1016/j.semarthrit.2013.09.005
   PubMed Web of Science ®Google Scholar
• Juge PA, Lee JS, Lau J, et al. Methotrexate and rheumatoid arthritis associated interstitial lung disease. Eur Respir J. 2021 Feb;57(2):2000337.
   PubMed Web of Science ®Google Scholar
• Spagnolo P, Bonniaud P, Rossi G, et al. Drug-induced interstitial lung disease. Eur Respir J. 2022 Oct;60(4):2102776.
   PubMed Web of Science ®Google Scholar
• Yang L, Li B, Xu Y, et al. Pneumonitis with combined immune checkpoint inhibitors and chemoradiotherapy in locally advanced non-small-cell lung cancer: a systematic review and meta-analysis. Future Oncol. 2023 May;19(16):1151–1160.
   PubMed Web of Science ®Google Scholar
• O’Sullivan JM, Huddart RA, Norman AR, et al. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol. 2003 Jan;14(1):91–96.
   PubMed Web of Science ®Google Scholar
• Matsuno O. Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res. 2012 May 31;13(1):39. doi: 10.1186/1465-9921-13-39
   PubMedGoogle Scholar
• Jessurun GA, Crijns HJ. Amiodarone pulmonary toxicity. BMJ. 1997 Mar 1;314(7081):619–620. doi: 10.1136/bmj.314.7081.619
   PubMedGoogle Scholar
• Vahid B, Marik PE. Pulmonary complications of novel antineoplastic agents for solid tumors. Chest. 2008 Feb;133(2):528–538. doi: 10.1378/chest.07-0851
   PubMed Web of Science ®Google Scholar
• Takano T, Ohe Y, Kusumoto M, et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer. 2004 Jul;45(1):93–104.
   PubMed Web of Science ®Google Scholar
• Atabai K, Ishigaki M, Geiser T, et al. Keratinocyte growth factor can enhance alveolar epithelial repair by nonmitogenic mechanisms. Am J Physiol Lung Cell Mol Physiol. 2002 Jul;283(1):L163–9.
   PubMed Web of Science ®Google Scholar
• Schnyder B, Pichler WJ. Mechanisms of drug-induced allergy. Mayo Clin Proc. 2009 Mar;84(3):268–272. doi: 10.4065/84.3.268
   PubMed Web of Science ®Google Scholar
• Adair K, Meng X, Naisbitt DJ. Drug hapten-specific T-cell activation: Current status and unanswered questions. Proteomics. 2021 Sep;21(17–18):e2000267. doi: 10.1002/pmic.202000267
   PubMed Web of Science ®Google Scholar
• Landsteiner K, Jacobs J. Studies on the sensitization of animals with simple chemical compounds. J Exp Med. 1935 Apr 30;61(5):643–656. doi: 10.1084/jem.61.5.643
   PubMedGoogle Scholar
• Pichler WJ, Adam J, Daubner B, et al. Drug hypersensitivity reactions: pathomechanism and clinical symptoms. Med Clin North Am. 2010 Jul;94(4):645–64xv. doi: 10.1016/j.mcna.2010.04.003
   PubMed Web of Science ®Google Scholar
• Pichler WJ. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol. 2002 Aug;2(4):301–305. doi: 10.1097/00130832-200208000-00003
   PubMed Web of Science ®Google Scholar
• Matzinger P. The danger model: a renewed sense of self. Science. 2002 Apr 12;296(5566):301–305. doi: 10.1126/science.1071059
   PubMed Web of Science ®Google Scholar
• Distefano G, Fanzone L, Palermo M, et al. HRCT patterns of drug-induced interstitial lung diseases: a review. Diagn (Basel). 2020 Apr 22;10(4):244. doi: 10.3390/diagnostics10040244
   PubMedGoogle Scholar
• Raghu G, Remy-Jardin M, Ryerson CJ, et al. Diagnosis of hypersensitivity pneumonitis in adults. An official ATS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2020 Aug 1;202(3):e36–e69. doi: 10.1164/rccm.202005-2032ST
   PubMed Web of Science ®Google Scholar
• Konopka KE, Nguyen T, Jentzen JM, et al. Diffuse alveolar damage (DAD) resulting from coronavirus disease 2019 infection is morphologically indistinguishable from other causes of DAD. Histopathology. 2020 Oct;77(4):570–578.
   PubMed Web of Science ®Google Scholar
• Brieva J. Cyclophosphamide-induced acute respiratory distress syndrome. Respirology. 2007 Sep;12(5):769–773. doi: 10.1111/j.1440-1843.2007.01128.x
   PubMed Web of Science ®Google Scholar
• Baumann H, Fichtenkamm P, Schneider T, et al. Rapid onset of amiodarone induced pulmonary toxicity after lung lobe resection - a case report and review of recent literature. Ann Med Surg. 2017 Sep;21:53–57. doi: 10.1016/j.amsu.2017.07.034
   PubMedGoogle Scholar
• Bartal C, Sagy I, Barski L. Drug-induced eosinophilic pneumonia: A review of 196 case reports. Medicine (Baltimore). 2018 Jan;97(4):e9688. doi: 10.1097/MD.0000000000009688
   PubMed Web of Science ®Google Scholar
• Mercier T, Castagnola E, Marr KA, et al. Defining galactomannan positivity in the updated EORTC/MSGERC consensus definitions of invasive fungal diseases. Clin Infect Dis. 2021 Mar 12;72(Suppl 2):S89–S94. doi: 10.1093/cid/ciaa1786
   PubMedGoogle Scholar
• Coudert B, Bailly F, Lombard JN, et al. Amiodarone pneumonitis. Bronchoalveolar lavage findings in 15 patients and review of the literature. Chest. 1992 Oct;102(4):1005–1012.
   PubMed Web of Science ®Google Scholar
• Costabel U, Uzaslan E, Guzman J. Bronchoalveolar lavage in drug-induced lung disease. Clin Chest Med. 2004 Mar;25(1):25–35. doi: 10.1016/S0272-5231(03)00143-6
   PubMed Web of Science ®Google Scholar
• Kakugawa T, Yokota S, Ishimatsu Y, et al. Serum heat shock protein 47 levels in patients with drug-induced lung disease. Respir Res. 2013 Nov 20;14(1):133. doi: 10.1186/1465-9921-14-133
   PubMedGoogle Scholar
• King TE Jr., Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014 May 29;370(22):2083–2092. doi: 10.1056/NEJMoa1402582
   PubMed Web of Science ®Google Scholar
• Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014 May 29;370(22):2071–2082. doi: 10.1056/NEJMoa1402584
   PubMed Web of Science ®Google Scholar
• Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019 Oct 31;381(18):1718–1727. doi: 10.1056/NEJMoa1908681
   PubMed Web of Science ®Google Scholar
• Harada G, Santini FC, Canedo F, et al. Successful osimertinib rechallenge following drug-induced pneumonitis after previous anti-PDL1 exposure. Ecancermedicalscience. 2019;13:970. doi: 10.3332/ecancer.2019.970
   PubMed Web of Science ®Google Scholar
• Nitawaki T, Sakata Y, Kawamura K, et al. Case report: continued treatment with alectinib is possible for patients with lung adenocarcinoma with drug-induced interstitial lung disease. BMC Pulm Med. 2017 Dec 6;17(1):173. doi: 10.1186/s12890-017-0519-y
   PubMedGoogle Scholar
• Sharma A, Provenzale D, McKusick A, et al. Interstitial pneumonitis after low-dose methotrexate therapy in primary biliary cirrhosis. Gastroenterology. 1994 Jul;107(1):266–270. doi: 10.1016/0016-5085(94)90085-X
   PubMed Web of Science ®Google Scholar
• Imokawa S, Colby TV, Leslie KO, et al. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J. 2000 Feb;15(2):373–381.
   PubMed Web of Science ®Google Scholar
• Mankikian J, Favelle O, Guillon A, et al. Initial characteristics and outcome of hospitalized patients with amiodarone pulmonary toxicity. Respir med. 2014 Apr;108(4):638–646.
   PubMed Web of Science ®Google Scholar
• Chikura B, Lane S, Dawson JK. Clinical expression of leflunomide-induced pneumonitis. Rheumatology (Oxford). 2009 Sep;48(9):1065–1068. doi: 10.1093/rheumatology/kep050
   PubMed Web of Science ®Google Scholar
• Tomii K, Kato T, Takahashi M, et al. Pemetrexed-related interstitial lung disease reported from post marketing surveillance (malignant pleural mesothelioma/non-small cell lung cancer). Jpn J Clin Oncol. 2017 Apr 1;47(4):350–356. doi: 10.1093/jjco/hyx010
   PubMed Web of Science ®Google Scholar
• Osawa M, Kudoh S, Sakai F, et al. Clinical features and risk factors of panitumumab-induced interstitial lung disease: a postmarketing all-case surveillance study [research support, non-U.S. Gov’t]. Int J Clin Oncol. 2015 Dec;20(6):1063–1071.
   PubMed Web of Science ®Google Scholar
• Yoshii N, Suzuki T, Nagashima M, et al. Clarification of clinical features of interstitial lung disease induced by irinotecan based on postmarketing surveillance data and spontaneous reports. Anticancer Drugs. 2011 Jul;22(6):563–8.
   PubMed Web of Science ®Google Scholar
• Fujimoto D, Kato R, Morimoto T, et al. Characteristics and prognostic impact of pneumonitis during systemic anti-cancer therapy in patients with advanced non-small-cell lung cancer. PloS One. 2016;11(12):e0168465. doi: 10.1371/journal.pone.0168465
   PubMed Web of Science ®Google Scholar
• Abuhelwa Z, Alloghbi A, Alqahtani A, et al. Trastuzumab deruxtecan-induced interstitial lung disease/pneumonitis in ERBB2-positive advanced solid malignancies: a systematic review. Drugs. 2022 Jun;82(9):979–987. doi: 10.1007/s40265-022-01736-w
   PubMed Web of Science ®Google Scholar
• Higenbottam T, Kuwano K, Nemery B, et al. Understanding the mechanisms of drug-associated interstitial lung disease. Br J Cancer. 2004 Aug;91 Suppl 2(Suppl 2):S31–7. doi: 10.1038/sj.bjc.6602065
   PubMedGoogle Scholar
• Delanoy N, Pecuchet N, Fabre E, et al. Bleomycin-induced pneumonitis in the treatment of ovarian sex cord-stromal tumors: a systematic review and meta-analysis. Int J Gynecol Cancer. 2015 Nov;25(9):1593–1598.
   PubMed Web of Science ®Google Scholar
• Necchi A, Miceli R, Oualla K, et al. Effect of bleomycin administration on the development of pulmonary toxicity in patients with metastatic germ cell tumors receiving first-line chemotherapy: a meta-analysis of randomized studies. Clin Genitourin Cancer. 2017 Apr;15(2):213–220 e5.
   PubMed Web of Science ®Google Scholar
• Stamatoullas A, Brice P, Bouabdallah R, et al. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. Br J Haematol. 2015 Jul;170(2):179–184.
   PubMed Web of Science ®Google Scholar
• Jona A, Miltenyi Z, Poliska S, et al. Effect of bleomycin hydrolase gene polymorphism on late pulmonary complications of treatment for Hodgkin Lymphoma. PloS One. 2016;11(6):e0157651. doi: 10.1371/journal.pone.0157651
   PubMed Web of Science ®Google Scholar
• Kroupa M, Polivkova Z, Rachakonda S, et al. Bleomycin-induced chromosomal damage and shortening of telomeres in peripheral blood lymphocytes of incident cancer patients. Genes Chromosomes Cancer. 2018 Feb;57(2):61–69.
   PubMed Web of Science ®Google Scholar
• Wolkowicz J, Sturgeon J, Rawji M, et al. Bleomycin-induced pulmonary function abnormalities. Chest. 1992 Jan;101(1):97–101.
   PubMed Web of Science ®Google Scholar
• Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med. 2012 Feb 2;366(5):399–408. doi: 10.1056/NEJMoa1111961
   PubMed Web of Science ®Google Scholar
• Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med. 2016 Jun 23;374(25):2419–2429. doi: 10.1056/NEJMoa1510093
   PubMed Web of Science ®Google Scholar
• Goldiner PL, Carlon GC, Cvitkovic E, et al. Factors influencing postoperative morbidity and mortality in patients treated with bleomycin. Br Med J. 1978 Jun 24;1(6128):1664–1667. doi: 10.1136/bmj.1.6128.1664
   PubMedGoogle Scholar
• White DA, Stover DE. Severe bleomycin-induced pneumonitis. Clinical features and response to corticosteroids. Chest. 1984 Nov;86(5):723–728. doi: 10.1378/chest.86.5.723
   PubMed Web of Science ®Google Scholar
• Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021 Dec 20;39(36):4073–4126. doi: 10.1200/JCO.21.01440
   PubMed Web of Science ®Google Scholar
• Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018 Dec 1;4(12):1721–1728. doi: 10.1001/jamaoncol.2018.3923
   PubMed Web of Science ®Google Scholar
• Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/Programmed death Ligand 1 therapy. J Clin Oncol. 2017 Mar;35(7):709–717.
   PubMed Web of Science ®Google Scholar
• Postow MA, Sidlow R, Hellmann MD, et al. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018 Jan 11;378(2):158–168. doi: 10.1056/NEJMra1703481
   PubMed Web of Science ®Google Scholar
• Suresh K, Naidoo J, Lin CT, et al. Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities. Chest. 2018 Dec;154(6):1416–1423.
   PubMed Web of Science ®Google Scholar
• Ali AK, Watson DE. Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies. Pharmacotherapy. 2017 Nov;37(11):1383–1390. doi: 10.1002/phar.2035
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016 Apr 9;387(10027):1540–1550. doi: 10.1016/S0140-6736(15)01281-7
   PubMed Web of Science ®Google Scholar
• Beattie J, Rizvi H, Fuentes P, et al. Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade. J Immunother Cancer. 2021 Feb;9(2):e001884.
   PubMed Web of Science ®Google Scholar
• Balaji A, Hsu M, Lin CT, et al. Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes. J Immunother Cancer. 2021 Jan;9(1):e001731.
   PubMed Web of Science ®Google Scholar
• Zhai X, Zhang J, Tian Y, et al. The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients. Cancer Biol Med. 2020 Aug 15;17(3):599–611. doi: 10.20892/j.issn.2095-3941.2020.0102
   PubMed Web of Science ®Google Scholar
• Nishino M, Sholl LM, Awad MM, et al. Sarcoid-Like Granulomatosis of the lung related to immune-checkpoint inhibitors: distinct clinical and imaging features of a unique immune-related adverse event. Cancer Immunol Res. 2018 Jun;6(6):630–635.
   PubMed Web of Science ®Google Scholar
• Cho HS, Kim SJ, Yoo JY. Sarcoidosis during treatment of pulmonary tuberculosis: a rare case report and review of the literature. J Int Med Res. 2021 Apr;49(4):3000605211001632. doi: 10.1177/03000605211001632
   Web of Science ®Google Scholar
• Dai HP, Ma F, Ren YH, et al. Expert consensus on the diagnosis and treatment of anticancer drug-induced interstitial lung disease. Curr Med Sci. 2023 Feb;43(1):1–12.
   PubMed Web of Science ®Google Scholar
• Naidoo J, Cottrell TR, Lipson EJ, et al. Chronic immune checkpoint inhibitor pneumonitis. J Immunother Cancer. 2020 Jun;8(1):e000840.
   PubMed Web of Science ®Google Scholar
• Mitra A, Barua A, Huang L, et al. From bench to bedside: the history and progress of CAR T cell therapy. Front Immunol. 2023;14:1188049. doi: 10.3389/fimmu.2023.1188049
   PubMed Web of Science ®Google Scholar
• Sun Z, Xie C, Liu H, et al. CD19 CAR-T cell therapy induced immunotherapy associated interstitial pneumonitis: a case report. Front Immunol. 2022;13:778192. doi: 10.3389/fimmu.2022.778192
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. N Engl J Med. 2019 Jan 3;380(1):45–56. doi: 10.1056/NEJMoa1804980
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017 Dec 28;377(26):2531–2544. doi: 10.1056/NEJMoa1707447
   PubMed Web of Science ®Google Scholar
• Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013 Apr 18;368(16):1509–1518. doi: 10.1056/NEJMoa1215134
   PubMed Web of Science ®Google Scholar
• Bondeelle L, Di Blasi R, Samy L, et al. CAR T cells-associated delayed lung toxicity – a case series. Eur Respir J. 2020;56:746.
   Web of Science ®Google Scholar
• Ding X, Ji W, Li J, et al. Radiation recall pneumonitis induced by chemotherapy after thoracic radiotherapy for lung cancer. Radiat Oncol. 2011 Mar 6;6(1):24. doi: 10.1186/1748-717X-6-24
   PubMedGoogle Scholar
• Thomas PS, Agrawal S, Gore M, et al. Recall lung pneumonitis due to carmustine after radiotherapy. Thorax. 1995 Oct;50(10):1116–1118.
   PubMed Web of Science ®Google Scholar
• Schweitzer VG, Juillard GJ, Bajada CL, et al. Radiation recall dermatitis and pneumonitis in a patient treated with paclitaxel. Cancer. 1995 Sep 15;76(6):1069–1072. doi: 10.1002/1097-0142(19950915)76:6<1069:AID-CNCR2820760623>3.0.CO;2-7
   PubMed Web of Science ®Google Scholar
• Vegesna V, Withers HR, WH M, et al. Adriamycin-induced recall of radiation pneumonitis and epilation in lung and hair follicles of mouse. Int J Radiat Oncol Biol Phys. 1992;23(5):977–981. doi: 10.1016/0360-3016(92)90902-T
   PubMed Web of Science ®Google Scholar
• Jan PR, Chang JW, Wu CE. Radiation recall pneumonitis: a rare syndrome that should Be recognized. Cancers (Basel). 2022 Sep 24;14(19):4642. doi: 10.3390/cancers14194642
   PubMed Web of Science ®Google Scholar
• Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis & Rheumat. 2021 Jul;73(7):1108–1123.
   PubMed Web of Science ®Google Scholar
• Cottin V, Bendstrup E, Bonniaud P, et al. The case of methotrexate and the lung: dr Jekyll and mr Hyde. Eur Respir J. 2021 Feb;57(2):2100079.
   PubMed Web of Science ®Google Scholar
• Kinder AJ, Hassell AB, Brand J, et al. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology (Oxford). 2005 Jan;44(1):61–66.
   PubMed Web of Science ®Google Scholar
• Fragoulis GE, Nikiphorou E, Larsen J, et al. Methotrexate-associated pneumonitis and rheumatoid arthritis-interstitial lung disease: Current concepts for the diagnosis and treatment. Front Med. 2019;6:238. doi: 10.3389/fmed.2019.00238
   PubMed Web of Science ®Google Scholar
• Schnabel A, Richter C, Bauerfeind S, et al. Bronchoalveolar lavage cell profile in methotrexate induced pneumonitis. Thorax. 1997 Apr;52(4):377–379.
   PubMed Web of Science ®Google Scholar
• Alarcón GS, Kremer JM, Macaluso M, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-lung study group. Ann Intern Med. 1997 Sep 1;127(5):356–364. doi: 10.7326/0003-4819-127-5-199709010-00003
   PubMed Web of Science ®Google Scholar
• Olson AL, Swigris JJ, Sprunger DB, et al. Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med. 2011 Feb 1;183(3):372–378. doi: 10.1164/rccm.201004-0622OC
   PubMed Web of Science ®Google Scholar
• Matson SM, Deane KD, Peljto AL, et al. Prospective identification of subclinical interstitial lung disease in a rheumatoid arthritis cohort is associated with the MUC5B promoter variant. Am J Respir Crit Care Med. 2022 Feb 15;205(4):473–476. doi: 10.1164/rccm.202109-2087LE
   PubMed Web of Science ®Google Scholar
• McDermott GC, Hayashi K, Yoshida K, et al. Prevalence and mortality associations of interstitial lung abnormalities in rheumatoid arthritis within a multicentre prospective cohort of smokers. Rheumatology (Oxford). 2023 Oct 23;62(SI3):SI286–SI295. doi: 10.1093/rheumatology/kead277
   PubMed Web of Science ®Google Scholar
• Solomon JJ, Swigris JJ, Kreuter M, et al. The attitudes and practices of physicians caring for patients with rheumatoid arthritis-associated interstitial lung disease: an international survey. Rheumatology (Oxford). 2022 Apr 11;61(4):1459–1467. doi: 10.1093/rheumatology/keab552
   PubMed Web of Science ®Google Scholar
• Huie TJ, Olson AL, Cosgrove GP, et al. A detailed evaluation of acute respiratory decline in patients with fibrotic lung disease: aetiology and outcomes. Respirology. 2010 Aug;15(6):909–917.
   PubMed Web of Science ®Google Scholar
• Xie M, Zhu C, Ye Y. Incidence, risk factors, and prognosis of acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis. BMC Pulm Med. 2023 Jul 11;23(1):255. doi: 10.1186/s12890-023-02532-2
   PubMed Web of Science ®Google Scholar
• Kiely P, Busby AD, Nikiphorou E, et al. Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts. BMJ Open. 2019 May 5;9(5):e028466. doi: 10.1136/bmjopen-2018-028466
   PubMed Web of Science ®Google Scholar
• Rojas-Serrano J, Herrera-Bringas D, Pérez-Román DI, et al. Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis. Clin Rheumatol. 2017 Jul;36(7):1493–1500.
   PubMed Web of Science ®Google Scholar
• Kim K, Woo A, Park Y, et al. Protective effect of methotrexate on lung function and mortality in rheumatoid arthritis-related interstitial lung disease: a retrospective cohort study. Ther Adv Respir Dis. 2022 Jan;16:17534666221135314. doi: 10.1177/17534666221135314
   Web of Science ®Google Scholar
• Sparks JA, Dellaripa PF, Glynn RJ, et al. Pulmonary adverse events in patients receiving low-dose methotrexate in the randomized, double-blind, placebo-controlled cardiovascular inflammation reduction trial. Arthritis & rheumat. 2020 Dec;72(12):2065–2071.
   PubMed Web of Science ®Google Scholar
• Rheumatology ACo. 2023 American College of Rheumatology (ACR) guideline for the screening and monitoring of interstitial lung disease in people with systemic autoimmune rheumatic disease. Guideline Summary American College Of Rheumatology2023. 2023 Dec. Available from: https://rheumatology.org/interstitial-lung-disease-guideline
   Google Scholar
• Jackevicius CA, Tom A, Essebag V, et al. Population-level incidence and risk factors for pulmonary toxicity associated with amiodarone. Am J Cardiol. 2011 Sep 1;108(5):705–710. doi: 10.1016/j.amjcard.2011.04.024
   PubMed Web of Science ®Google Scholar
• Papiris SA, Triantafillidou C, Kolilekas L, et al. Amiodarone: review of pulmonary effects and toxicity. Drug Saf. 2010 Jul 1;33(7):539–558. doi: 10.2165/11532320-000000000-00000
   PubMed Web of Science ®Google Scholar
• Kosseifi SG, Halawa A, Bailey B, et al. Reduction of amiodarone pulmonary toxicity in patients treated with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Ther Adv Respir Dis. 2009 Dec;3(6):289–294.
   PubMedGoogle Scholar
• Rotmensch HH, Belhassen B, Swanson BN, et al. Steady-state serum amiodarone concentrations: relationships with antiarrhythmic efficacy and toxicity. Ann Intern Med. 1984 Oct;101(4):462–469.
   PubMed Web of Science ®Google Scholar
• Wolkove N, Baltzan M. Amiodarone pulmonary toxicity. Can Respir J. 2009 Mar;16(2):43–48. doi: 10.1155/2009/282540
   PubMed Web of Science ®Google Scholar
• Kwok WC, Ma TF, Chan JWM, et al. A multicenter retrospective cohort study on predicting the risk for amiodarone pulmonary toxicity. BMC Pulm Med. 2022 Apr 5;22(1):128. doi: 10.1186/s12890-022-01926-y
   PubMed Web of Science ®Google Scholar
• Anai S, Nakayama Y, Gushiken H, et al. Diffuse alveolar hemorrhage and acute eosinophilic pneumonia: a rare form of amiodarone pulmonary toxicity diagnosed by bronchoalveolar lavage. J Cardiol Cases. 2023 Mar;27(3):93–96.
   PubMedGoogle Scholar
• Rodriguez-Garcia JL, Garcia-Nieto JC, Ballesta F, et al. Pulmonary mass and multiple lung nodules mimicking a lung neoplasm as amiodarone-induced pulmonary toxicity. Eur J Intern Med. 2001 Jul;12(4):372–376.
   PubMedGoogle Scholar
• Okayasu K, Takeda Y, Kojima J, et al. Amiodarone pulmonary toxicity: a patient with three recurrences of pulmonary toxicity and consideration of the probable risk for relapse. Intern Med. 2006;45(22):1303–1307. doi: 10.2169/internalmedicine.45.1800
   PubMed Web of Science ®Google Scholar
• Elliott LS, Henderson JC, Neradilek MB, et al. Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: a prospective pilot randomized controlled trial. PloS One. 2017;12(2):e0170905. doi: 10.1371/journal.pone.0170905
   PubMed Web of Science ®Google Scholar
• Tsermpini EE, ZN A-M, Ali BR, et al. Clinical implementation of drug metabolizing gene-based therapeutic interventions worldwide. Hum Genet. 2022 Jun;141(6):1137–1157. doi: 10.1007/s00439-021-02369-x
   PubMed Web of Science ®Google Scholar
• Walsh SLF, Mackintosh JA, Calandriello L, et al. Deep learning-based outcome prediction in progressive fibrotic lung disease using high-resolution computed tomography. Am J Respir Crit Care Med. 2022 Oct 1;206(7):883–891. doi: 10.1164/rccm.202112-2684OC
   PubMed Web of Science ®Google Scholar
• Felder FN, Walsh SLF. Exploring computer-based imaging analysis in interstitial lung disease: opportunities and challenges. ERJ Open Res. 2023 Jul;9(4):00145–2023. doi: 10.1183/23120541.00145-2023
   PubMedGoogle Scholar
• Yamakawa H, Oba T, Ohta H, et al. Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report. BMC Pulm Med. 2019 Aug 22;19(1):156. doi: 10.1186/s12890-019-0920-9
   PubMed Web of Science ®Google Scholar
• Scondotto G, Crisafulli S, Antonazzo IC, et al. Assessing intravitreal anti-VEGF drug safety using real-world data: methodological challenges in observational research. Expert Opin Drug Saf. 2022 Feb;21(2):205–214.
   PubMed Web of Science ®Google Scholar
• Trifiro G, Isgro V, Ingrasciotta Y, et al. Large-scale postmarketing surveillance of biological drugs for immune-mediated inflammatory diseases through an Italian distributed multi-database healthcare network: the VALORE project. BioDrugs. 2021 Nov;35(6):749–764.
   PubMed Web of Science ®Google Scholar